John Ruckdeschel

833 total citations
7 papers, 592 citations indexed

About

John Ruckdeschel is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, John Ruckdeschel has authored 7 papers receiving a total of 592 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Oncology, 2 papers in Pulmonary and Respiratory Medicine and 2 papers in Epidemiology. Recurrent topics in John Ruckdeschel's work include Lung Cancer Treatments and Mutations (2 papers), Sympathectomy and Hyperhidrosis Treatments (1 paper) and Selenium in Biological Systems (1 paper). John Ruckdeschel is often cited by papers focused on Lung Cancer Treatments and Mutations (2 papers), Sympathectomy and Hyperhidrosis Treatments (1 paper) and Selenium in Biological Systems (1 paper). John Ruckdeschel collaborates with scholars based in United States, Netherlands and Canada. John Ruckdeschel's co-authors include Paul S. Thomas, Giuseppe Giaccone, David Payne, Thomas E. Lad, Steven Piantadosi, David L. Ronis, Mark M. Zalupski, Peter C. Trask, Gregory P. Kalemkerian and Maha Hussain and has published in prestigious journals such as Journal of Clinical Oncology, CHEST Journal and Transplantation.

In The Last Decade

John Ruckdeschel

7 papers receiving 568 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Ruckdeschel United States 6 366 207 158 140 107 7 592
A Maestri Italy 12 328 0.9× 25 0.1× 192 1.2× 99 0.7× 60 0.6× 30 581
Alison Cox United Kingdom 4 184 0.5× 54 0.3× 38 0.2× 108 0.8× 19 0.2× 4 481
Haomin Yang China 11 120 0.3× 40 0.2× 52 0.3× 37 0.3× 35 0.3× 29 349
Laura Farnan United States 12 168 0.5× 33 0.2× 111 0.7× 71 0.5× 38 0.4× 38 464
Hammond Ec 8 189 0.5× 53 0.3× 145 0.9× 154 1.1× 7 0.1× 29 745
Elżbieta Cipora Poland 12 144 0.4× 37 0.2× 34 0.2× 42 0.3× 37 0.3× 55 362
Hyeonyoung Ko South Korea 11 74 0.2× 41 0.2× 59 0.4× 52 0.4× 45 0.4× 31 354
Michèle Deschamps Canada 12 247 0.7× 40 0.2× 36 0.2× 118 0.8× 15 0.1× 15 563
Mary Phillips United Kingdom 13 242 0.7× 103 0.5× 62 0.4× 23 0.2× 26 0.2× 36 686
Avonne E. Connor United States 12 248 0.7× 32 0.2× 50 0.3× 60 0.4× 21 0.2× 57 443

Countries citing papers authored by John Ruckdeschel

Since Specialization
Citations

This map shows the geographic impact of John Ruckdeschel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Ruckdeschel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Ruckdeschel more than expected).

Fields of papers citing papers by John Ruckdeschel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Ruckdeschel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Ruckdeschel. The network helps show where John Ruckdeschel may publish in the future.

Co-authorship network of co-authors of John Ruckdeschel

This figure shows the co-authorship network connecting the top 25 collaborators of John Ruckdeschel. A scholar is included among the top collaborators of John Ruckdeschel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Ruckdeschel. John Ruckdeschel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Karp, Daniel D., Sandra J. Lee, Steven M. Keller, et al.. (2013). Randomized, Double-Blind, Placebo-Controlled, Phase III Chemoprevention Trial of Selenium Supplementation in Patients With Resected Stage I Non–Small-Cell Lung Cancer: ECOG 5597. Journal of Clinical Oncology. 31(33). 4179–4187. 82 indexed citations
2.
Northouse, Laurel, Darlene Mood, Ann Schafenacker, et al.. (2012). Randomized clinical trial of a brief and extensive dyadic intervention for advanced cancer patients and their family caregivers. Psycho-Oncology. 22(3). 555–563. 191 indexed citations
3.
Gadgeel, Shirish M., Martin J. Edelman, Manuel Valdivieso, et al.. (2009). Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 27(15_suppl). e19007–e19007. 28 indexed citations
4.
Lad, Thomas E., Steven Piantadosi, Paul S. Thomas, et al.. (1994). A Prospective Randomized Trial to Determine the Benefit of Surgical Resection of Residual Disease Following Response of Small Cell Lung Cancer to Combination Chemotherapy. CHEST Journal. 106(6). 320S–323S. 225 indexed citations
5.
Ruckdeschel, John, et al.. (1985). Chemotherapy for esophageal cancer with mitoguazone, methotrexate, bleomycin, and cisplatin.. PubMed. 69(1). 21–3. 7 indexed citations
6.
Ruckdeschel, John, et al.. (1977). APPLICATION OF LASER CYTOMETRY TO THE ANALYSIS OF IMMUNOLOGICALLY INDUCED IN VITRO LYMPHOCYTE RESPONSIVENESS. Transplantation. 23(5). 396–403. 4 indexed citations
7.
Ruckdeschel, John, Robert G. Martin, Roger W. Byhardt, et al.. (1975). RADIATION-RELATED PERICARDIAL EFFUSIONS IN PATIENTS WITH HODGKINʼS DISEASE. Medicine. 54(3). 245–259. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026